

**CT-guided
percutaneous radiofrequency ablation of
pulmonary malignancies**

A thesis submitted for partial fulfillment of M.D. degree in
Radio-diagnosis and intervention

By

AHMED SAMIR ZAREA
M.Sc. IN RADIODIAGNOSIS, AIN SHAMS UNIVERSITY

Under Supervision of

DR. WAHID HUSSEIN TANTAWY
PROFESSOR OF RADIODIAGNOSIS, AIN SHAMS
UNIVERSITY

DR. AHMED SAMIR IBRAHIM
ASSISTANT PROFESSOR OF RADIODIAGNOSIS, AIN
SHAMS UNIVERSITY

DR. MERHAN AHMED NASR
LECTURER OF RADIODIAGNOSIS, AIN SHMS
UNIVERSITY

**Faculty of medicine
Ain Shams University
2013**

حرق أورام الرئة بواسطة التردد الحراري

تشخيصية

مقدمة من

الطبيب/ أحمد سمير زارع

تحت إشراف

الدكتور/ وحيد حسين طنطاوي

أستاذ الأشعة التشخيصية
كلية الطب- جامعة عين شمس

الدكتور/ أحمد سمير إبراهيم

أستاذ مساعد الأشعة التشخيصية
كلية الطب- جامعة عين شمس

الدكتورة/ ميرهان أحمد نصر

مدرس الأشعة التشخيصية
كلية الطب- جامعة عين شمس

كلية الطب

جامعة عين شمس

Acknowledgement

First of all, I thank **Allah** who gave me the power to finish this work.

I would like to express my deepest gratitude and cardinal appreciation to **Prof. Dr. Wahid Hussin Tantawy** Professor of radio diagnosis, Faculty of Medicine, Ain Shams University, for his kind Guidance and supervision.

Thanks to **Dr. Ahmed Samir Ibrahim** Professor of Radio diagnosis, Faculty of Medicine, Ain Shams University, for his supervision and participation in this work.

Thanks to **Dr. Merihan Ahmed Nasr** lecturer of Radio diagnosis, Faculty of Medicine, Ain Shams University, for her supervision and participation in this work.

Last but not least I would like to express my best regards and thanks to all who gave me a hand while working on this research and I'd like to dedicate this work to my beloved **Family** who supported me to complete this work.

List of Abbreviations

ACCP:	American College of Chest Physician
AJCC:	American Joint Committee on Cancer
AS:	Analgosedation
BAC:	Bronchioloalveolar carcinoma
BOS:	Boston Scientific
BPF:	Broncho pleural fistula
BTS:	British Thoracic Society
CEA:	Carcinoembryonic antigen
CT:	Computed tomography
ECG:	Electric cardiogram.
FDG:	Fluorodeoxyglucose;
GA:	General anesthesia
GGO:	Ground glass opacification
HU:	Hounsfield units
IASLC:	International Association for the Study of Lung Cancer
INR:	International normalized ratio
LCNEC:	large cell neuroendocrine carcinoma
MRI:	Magnetic resonance imaging
MWA:	Microwave Ablation
NSAID:	Non-steroidal anti-inflammatory drugs
NSCLC:	Non-small cell lung cancer
PET:	Positron emission tomography
PMCT :	Percutaneous Microwave Coagulation Therapy

List of Abbreviations

PSP:	Primary spontaneous pneumothorax
PT:	Prothrombin time
RECIST:	Response Evaluation Criteria in Solid Tumors
RF:	Radiofrequency
RFA:	Radiofrequency ablation
SCC	Squamous cell carcinoma
SCLC:	Small cell lung cancer
SUV:	Standardized uptake value
UICC:	Union Internationale Contre le Cancer
US:	Ultrasonography
VL:	Valleylab
WHO:	World Health Organization

List of Figures

Fig. No.	Title	Page No.
1	<i>Lung tissue results</i>	16
2	<i>Schematic shows ionic agitation by alternating electric currents.</i>	17
3	<i>Various radiofrequency (RF) electrodes</i>	20
4	<i>Multitined expandable probe</i>	23
5	<i>Valley Lab Cool-Tip cluster probe</i>	23
6	<i>RF devices</i>	24
7	<i>CT suite during lung RFA.</i>	36
8	<i>CT fluoroscopy-guided radiofrequency (RF) ablation in patient with metastatic colon cancer to the right upper lobe.</i>	37
9	<i>case of MWA</i>	41
10	<i>Laser ablation system</i>	43
11	<i>steps in the cryoablation process</i>	44
12	<i>CT image for a patient undergoing radiofrequency ablation</i>	47
13	<i>Left upper lobe (LUL) tumor treated with RFA</i>	48

List of Figures

Fig. No.	Title	Page No.
14	<i>Radiofrequency ablation of right lower lobe colorectal metastasis.</i>	49
15	<i>Radiofrequency ablation of left upper lobe metastasis from colon cancer</i>	50
16	<i>RFA of middle lobe lesion (squamous cell carcinoma) of a 67-year-old male</i>	51
17	<i>Peripherally situated squamous cell carcinoma in the upper lobe of the right lung of a 58-year old man underwent RFA</i>	52
18	<i>Case of Immediate post-procedural pneumothorax</i>	57
19	<i>Case of Parenchymal hemorrhage seen immediately following ablation</i>	61
20	<i>Case of post ablation cavity at the treatment site with an air-fluid level.</i>	63
21	<i>Valley lab RF Ablation System.</i>	78
22	<i>Cool-tip Technology Single Electrode Kits.</i>	78
23	<i>Distribution of the percentage of patients according to gender</i>	80
24	<i>Mean age distribution according to gender</i>	81
25	<i>Distribution of number of patients with single or 2 parenchymal lesions</i>	81

List of Figures

Fig. No.	Title	Page No.
26	<i>percentage of the location of the lesions</i>	82
27	<i>Distribution of the mean values of the lesion size according to location prior to ablation</i>	84
28	<i>Distribution of the mean values of the lesion SUV according to location prior to ablation</i>	84
29	<i>Distribution of the mean values of the lesion size according to location 6 months post-ablation</i>	87
30	<i>Distribution of the mean values of the lesion SUV according to location 6 months post-ablation</i>	87
31	<i>6-month post ablation cure rate</i>	88
32	<i>Distribution of the mean values of the lesion size according to location 1 year post-ablation</i>	91
33	<i>Distribution of the mean values of the lesion size according to location 1 year post-ablation</i>	91
34	<i>1 year post ablation cure rate</i>	92
35	<i>Comparison between the lesion size according to location</i>	94
36	<i>Comparison between the lesion SUV according to location</i>	94
37	<i>Comparison between the lesion size at pre-ablation, 6 months and 1 year post-ablation</i>	95
38	<i>Comparison between the lesion SUV at pre-ablation, 6 months and 1 year post-ablation</i>	95

List of Figures

Fig. No.	Title	Page No.
39	<i>Post procedure complications.</i>	97
40	<i>Case 1</i>	98-99
41	<i>Case 2</i>	101-104
42	<i>Case 3</i>	106-110
43	<i>Case 4</i>	111-112
44	<i>Case 5</i>	113-114
45	<i>Case 6</i>	115-116
46	<i>Case 7</i>	117-119
47	<i>Case 8</i>	120-122
48	<i>Case 9</i>	123-124
49	<i>Case 10</i>	126-127
50	<i>Case 11</i>	128-129
51	<i>Case 12</i>	130-131

List of Tables

Table No.	Title	Page No.
1	<i>TNM descriptors Primary tumor (T) staging</i>	12
2	<i>Regional lymph nodes (N) staging</i>	13
3	<i>Distant metastasis (M) staging</i>	13
4	<i>TNM-staging system</i>	14
5	<i>IASLC Lung Cancer Staging Project</i>	14
6	<i>Selection Criteria to determine When to Use RFA</i>	27
7	<i>Types of complications</i>	53
8	<i>Summary of success rates for management strategies for primary spontaneous pneumothorax</i>	59
9	<i>Modified RECIST Criteria</i>	74
10	<i>Age distribution</i>	80
11	<i>Pre-ablative descriptive analysis of the size and SUV values</i>	83
12	<i>6 months post-ablative descriptive analysis</i>	86
13	<i>6 months post-ablative mean descriptive analysis</i>	87

List of Tables

14	<i>1 year post-ablative descriptive analysis</i>	90
15	<i>1 year post-ablative mean descriptive analysis</i>	91
16	<i>Demonstration to Compare between the size and SUV at pre-ablation, 6 months and 1 year post-ablation</i>	93
17	<i>Demonstration to Compare between the mean size and SUV of all ablated lesions at pre-ablation, 6 months and 1 year post-ablation</i>	95

Contents

<i>Title</i>	<i>Page</i>
Introduction & Aim of the work	1
Pathology of lung tumors	3
Physical principles of radiofrequency ablation	15
Technical Principles of radiofrequency ablation and other ablation groups	25
Imaging evaluation and follow up	45
Patients and methods	76
Results	80
Illustrative cases	98
Discussion	132
Summary and Conclusion	151
References	154
Arabic summary	_____

1- Introduction:

Lung cancer is the leading cause of cancer deaths. The survival rates for lung cancers diagnosed at the earliest stage are higher, with approximately 49% surviving for five years or longer. Most lung tumors are malignant. This means that they invade and destroy the healthy tissues around them and can spread throughout the body **(Stöppler, 2007)**.

Treatment decisions in lung cancer depend on whether small cell lung cancer (SCLC) or non small cell lung cancer (NSCLC) is present. Treatment also depends on tumor stage, particularly in NSCLC. A person's general physical condition (the ability to withstand treatment procedures) is also taken into account. The most widely used therapies for lung cancer are surgery, chemotherapy, and radiation therapy. Surgery is the preferred treatment for patients with early stage NSCLC. Unfortunately, 60%-80% of patients have advanced or metastatic disease and are not suitable candidates for surgery **(Stöppler, 2007)**.

Surgery is not widely used in SCLC. Because SCLC spreads widely and rapidly through the body, removing it all by surgery usually is impossible. Chemotherapy and radiation may lead to a cure in a small number of patients. These therapies result in shrinking of the tumor and are known to prolong life for extended periods in most patients. Chemotherapy and radiation are very effective at relieving symptoms. Inoperable NSCLC are treated with chemotherapy or a combination of chemotherapy and radiation **(Stöppler, 2007)**.

Many patients are poor surgical candidates owing to insufficient cardiopulmonary function, old age, or other medical co-morbidities as well as those with pulmonary metastasis tumors, a life-threatening event with bad survival rates. In recent years, tumor heating ablation such as radiofrequency ablation (RFA) under the guidance of image has been proved to be an alternative treatment method for these patients with definite effects **(Lu et al., 2012)**.

RFA is not intended to replace surgery, radiation therapy or chemotherapy in all patients. It may be effective when used alone or in conjunction with these treatments (**RadiologyInfo, 2014**).

A number of patients with primary bronchogenic carcinoma and some patients with isolated lung metastases are not suitable for operation due to comorbid disease. Conventional treatment with radiation and/or systemic chemotherapy may not significantly improve survival in these patients. RFA is a minimally invasive, effective, and safe method for the treatment of some malignant and benign conditions. Recent improvements in technology have made it possible to treat larger lesions by RFA and this has led to wider clinical applications (**Schaefer, et al., 2003**).

2- Aim of work:

The goal of this study is to assess the role of CT guided radiofrequency ablation in treatment of lung tumors.

Epidemiology

Lung cancer is the leading cause of cancer death in the United States and around the world (**Siegel et al., 2011**).

According to National Cancer Institute - in Egypt, primary malignant tumors of the respiratory system were the fifth most common tumors (578 cases) in this registry material, constituting 5.90% of total malignancy, with high male predominance of 73% and high adult predominance 98.62%. Malignant tumors of the lower respiratory system including the lungs and bronchi constituted 24.16% of respiratory organ malignancies, and 1.54% of total malignancy (**Mokhtar et al., 2007**).

The 1-year relative survival for lung cancer increased from 37% in 1975-1979 to 44% in 2005-2008, largely due to improvements in surgical techniques and combined therapies. However, the 5-year survival rate for all stages combined is only 16%. Only 15% of lung cancers are diagnosed at a localized stage, for which the 5-year survival rate is 52%. The 5-year survival for small cell lung cancer (6%) is lower than that for non-small cell (18%) (**American Cancer Society, 2013**).

The epidemic among women followed that among men, with a sharp rise in rates from the 1960s to the present, propelling lung cancer to become the most frequent cause of female cancer mortality (**American Cancer Society, 2006**).

Pathogenesis of lung cancer

The cancer cell evolves through a series of steps from normal , initiated and pre-neoplastic to pre-malignant and finally to highly malignant neoplasm. The three major steps in this process are **initiation**, **promotion** and tumour **progression** (**van Zandwijk, 2001**).

A single brief exposure to a carcinogen induces changes in the tissue , termed **initiation**. **Promotion** is ability of a compound to induce an area of proliferation in initiated tissue and stimulate tumour formation. Tumor